Corxel

CORXEL (formerly Ji Xing Pharmaceuticals, founded 2019) is a clinical-stage biopharmaceutical company headquartered in the United States and China, focused on developing innovative therapies for patients with cardiometabolic conditions. The company's strategy centers on identifying and in-licensing clinical-stage assets against validated cardiometabolic targets — including obesity, type 2 diabetes, hypertension, and acute cardiovascular events — and advancing them through mid- and late-stage development across global and regional pathways. Its lead program, CX11, is an oral small-molecule GLP-1 receptor agonist in Phase II development for obesity and type 2 diabetes. In January 2026, CORXEL completed a $287 million Series D1 financing to advance its cardiometabolic pipeline.